Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines

Sorafenib has long been the only approved systemic therapy for advanced hepatocellular carcinoma (HCC), but most patients show primary or acquired drug resistance. In the present study, RNA was extracted from sorafenib-resistant and -sensitive clones of the HCC cell lines HepG2 and Huh7. Protein-pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhi, He, Cheng-Zu, Qin, Ya-Qin, Liao, Jian-Jun, Huang, Shang-Tao, Mo, Steven, Li, Hong-Mian, Lin, Jian-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762478/
https://www.ncbi.nlm.nih.gov/pubmed/33234725
http://dx.doi.org/10.18632/aging.104195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762478/
https://www.ncbi.nlm.nih.gov/pubmed/33234725
http://dx.doi.org/10.18632/aging.104195

Ejemplares similares